Tirz Rx vs Ozempic: comparing tirzepatide and semaglutide

Last updated 2026-07-27

What's the actual difference between tirzepatide and Ozempic?

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist made by Novo Nordisk and FDA-approved for type 2 diabetes ^[1]. Tirzepatide is a dual GIP/GLP-1 receptor agonist made by Eli Lilly, sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management ^[2][3]. Both are once-weekly injectable peptides. The core mechanical difference is that semaglutide activates one gut hormone receptor (GLP-1), while tirzepatide activates two (GLP-1 and GIP), which is why researchers describe it as a "twincretin." Neither drug is interchangeable with the other by name. Ozempic is not approved for weight loss in the U.S.; Novo Nordisk's weight-loss version of semaglutide is sold as Wegovy, at higher doses than Ozempic uses. If your goal is weight loss, the honest comparison is Zepbound vs. Wegovy, or tirzepatide vs. semaglutide as compounds. "Ozempic" gets used as shorthand for the whole GLP-1 category in casual conversation, but that's imprecise and worth correcting up front. It's also worth being clear that "Tirz Rx" is not a drug brand or a manufacturer. It's a provider-reviewed access point for tirzepatide prescribing; it doesn't compound, manufacture, or sell the medication itself. Any comparison of "Tirz Rx vs Ozempic" really means tirzepatide vs. semaglutide, the two active compounds.

Which one produces more weight loss, tirzepatide or semaglutide?

Tirzepatide wins on average weight loss in every trial comparison run so far, including a direct head-to-head. In SURMOUNT-5 (NCT05822830), adults without diabetes on tirzepatide lost an average of 20.2% of body weight over 72 weeks, compared to 13.7% on semaglutide 2.4 mg ^[4]. That's not a modeled comparison, it's a real randomized trial that put both drugs against each other in the same population. Looking at the individual trials: in SURMOUNT-1 (NCT04184622), tirzepatide at the 15 mg dose produced 20.9% average weight loss at 72 weeks in adults with obesity or overweight and at least one weight-related condition, versus 3.1% for placebo ^[5]. In STEP 1 (NCT03548935), semaglutide 2.4 mg produced 14.9% average weight loss at 68 weeks versus 2.4% for placebo ^[6]. For type 2 diabetes, the pattern holds. SURPASS-2 (NCT03987919) compared tirzepatide directly against semaglutide 1 mg in people with type 2 diabetes and found tirzepatide produced greater reductions in both HbA1c and body weight at all three doses tested ^[7]. The New England Journal of Medicine report on SURPASS-2 concluded tirzepatide was "noninferior and superior" to semaglutide for glycemic control across the studied doses ^[7]. None of this means semaglutide is a weak drug. A 13 to 15% average body weight loss is a genuinely strong result by the standards of any weight-loss intervention before this drug class existed. Tirzepatide's edge is real and trial-confirmed, but it's a difference in degree, not a difference between something that works and something that doesn't.

How do the dosing schedules compare?

Both drugs use gradual dose escalation to reduce nausea, and both are once-weekly subcutaneous injections. The specific numbers differ. | | Tirzepatide (Zepbound/Mounjaro) | Semaglutide (Ozempic/Wegovy) |

What are the side effects of tirzepatide vs. Ozempic?

Both drugs share the same core side-effect profile because both slow gastric emptying and act on appetite-regulating hormone pathways. The most common complaints for both are nausea, diarrhea, vomiting, constipation, and decreased appetite ^[3][8]. In the SURMOUNT-1 trial, gastrointestinal side effects were the most frequently reported adverse events with tirzepatide, described in the trial report as "mild to moderate" and most common during dose escalation ^[5]. In STEP 1, semaglutide showed a similar pattern, with nausea reported in about 44% of the semaglutide group versus 16% on placebo ^[6]. Both drugs carry the same boxed warning: an increased risk of thyroid C-cell tumors was observed in rodent studies, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[3][8]. This warning is class-wide for GLP-1 receptor agonists and dual agonists, not specific to one brand. Other shared risks flagged on both labels include acute pancreatitis, gallbladder disease (including cholelithiasis and cholecystitis), acute kidney injury (often secondary to dehydration from GI symptoms), hypoglycemia when combined with insulin or sulfonylureas, and hypersensitivity reactions ^[3][8]. Neither drug should be used during pregnancy; both labels recommend discontinuing at least two months before a planned pregnancy given the time needed to clear the drug. If you're managing injection logistics and want to reduce site reactions or rotation errors, see Tirz Rx injection sites and Tirz Rx how to inject.

Is tirzepatide safer or riskier than semaglutide?

Neither drug has shown a clearly worse safety signal than the other in head-to-head data; they're closely matched. In SURPASS-2, the overall rates of adverse events were similar between tirzepatide and semaglutide arms, with GI events being the most common in both groups and discontinuation rates for adverse events in a comparable range across doses ^[7]. Where the two diverge slightly: tirzepatide's dual GIP action means some patients report less nausea at comparable points in titration, though this isn't consistent across every study and shouldn't be treated as guaranteed. Because tirzepatide has a higher maximum weight-loss effect, the practical safety conversation often shifts to whether faster or larger weight loss increases risk of gallstones, since rapid weight loss itself (regardless of drug) is a known risk factor for gallbladder disease ^[3]. Neither drug is a good fit for people with a personal or family history of MTC or MEN 2, a history of pancreatitis, severe GI disease (including gastroparesis), or diabetic retinopathy requiring active treatment (a specific caution flagged for semaglutide in cardiovascular outcomes data). Anyone with these conditions needs a real conversation with a prescriber, not a self-directed choice between the two drugs.

How does compounded tirzepatide differ from Zepbound or Mounjaro?

Compounded tirzepatide is not the same product as FDA-approved Zepbound or Mounjaro, and that distinction matters more than most marketing acknowledges. Zepbound and Mounjaro are manufactured by Eli Lilly in an FDA-inspected process, with each vial or pen tested against the approved specification. Compounded tirzepatide is prepared by a licensed compounding pharmacy, typically under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, and is legally permitted only when the commercially approved product is not reasonably available for a specific patient's needs, or when the prescriber requires a customized formulation (a different strength or an added ingredient the commercial product doesn't offer) ^[9]. The FDA has been explicit that compounded drugs, including compounded tirzepatide and semaglutide, "are not FDA-approved" and the agency "does not review compounded drugs for safety, effectiveness, or quality before they are marketed" ^[9]. In 2023 and 2024, FDA also issued warnings about compounded semaglutide and tirzepatide products made with salt forms (like semaglutide sodium or tirzepatide acetate) that are not the active ingredient in the approved drugs, and about counterfeit product entering the supply chain ^[10]. None of this means compounded tirzepatide is automatically unsafe. It means the quality control burden shifts from a federally regulated manufacturer to the individual compounding pharmacy, so where you source it from (and whether a licensed pharmacy is actually doing the compounding and dispensing) matters enormously. A provider-reviewed prescribing process, paired with a named, licensed fulfilling pharmacy, is the version of this that has real oversight built in. Tirz Rx's model is built around that provider-review step rather than around compounding the drug itself.

How much does tirzepatide cost compared to Ozempic?

List prices for both drugs run high without insurance, and list price is rarely what anyone actually pays. Eli Lilly's stated list price for Zepbound is around $1,059.87 per month for the standard dose without insurance, though the company has offered lower cash-pay prices for certain vial-based single-dose presentations sold through its direct-to-consumer LillyDirect program, in some cases starting around $349 to $499 per month for lower doses . Mounjaro's list price runs similarly high, in the neighborhood of $1,000+ per month before rebates or savings cards. Novo Nordisk lists Ozempic at roughly $997 to $1,000+ per month without insurance, and Wegovy at a comparable list price, though the company has also launched direct cash-pay options at lower price points for some doses through NovoCare . Insurance coverage for either drug varies enormously by plan, by diagnosis code (weight management vs. type 2 diabetes coverage rules differ), and by whether prior authorization is required. Compounded tirzepatide, when available, has generally run cheaper per month than either brand-name list price, which is a major reason patients ask about it, but the FDA's shortage-based allowance for compounding narrowed considerably after Lilly and the FDA confirmed tirzepatide was no longer in shortage in late 2024, which changed what's legally compoundable and by whom ^[9].

Which drug works faster, tirzepatide or semaglutide?

Both drugs show measurable weight loss within the first four to eight weeks, during the initial low-dose period, but neither is fast in the sense of dramatic short-term results. Most of the visible difference in trial data shows up by month three to four, once patients reach mid-range doses. In SURMOUNT-1, weight loss curves were still descending at the 72-week endpoint, meaning most participants hadn't plateaued even at the study's end ^[5]. STEP 1 showed a similar pattern with semaglutide, with the steepest early losses happening in the first 20 weeks as doses escalated, then continuing more gradually ^[6]. Neither drug produces most of its effect in the first month; the early weeks are largely about tolerance-building at low doses, not maximal fat loss. If your priority is speed rather than total percentage lost, the honest answer is that neither drug is meaningfully faster than the other in the first month or two. The separation in results shows up later, once tirzepatide's dual-hormone mechanism has more room to outperform at higher, longer-sustained doses. For a longer view on how a typical course is structured over months, Tirz Rx cycle length walks through what a realistic multi-month timeline looks like.

Do tirzepatide and semaglutide work the same way in the body?

Not exactly. Semaglutide is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a gut hormone that slows stomach emptying, increases insulin release in response to food, suppresses glucagon, and acts on brain regions that regulate appetite and satiety. Tirzepatide does all of that plus activates the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is a second incretin hormone, and in preclinical and early clinical research, combining GIP agonism with GLP-1 agonism appeared to improve insulin sensitivity and produce greater weight loss than GLP-1 agonism alone, which is the mechanistic rationale behind tirzepatide's stronger trial results ^[2][7]. Researchers sometimes call this dual mechanism a reason tirzepatide is more "metabolically potent" per unit dose, though that phrase is a simplification of a more complex receptor pharmacology story that's still being studied. The practical takeaway: this isn't just a stronger dose of the same drug. It's a genuinely different molecule hitting two receptor systems instead of one, and the trial data (more than the mechanism) is what should drive the comparison.

Can you switch between tirzepatide and Ozempic?

People do switch, usually for cost, side-effect tolerance, or insurance coverage reasons, but it should be done under medical supervision rather than as a self-managed swap. Because the two drugs use different titration scales (tirzepatide's mg amounts are not equivalent to semaglutide's mg amounts; a 5 mg tirzepatide dose is not the same relative strength as 5 mg of semaglutide, which doesn't even exist as a dose), there's no simple conversion chart, and a prescriber typically restarts titration at a low dose of the new drug rather than jumping to an equivalent middle dose. There isn't strong published trial data specifically studying mid-treatment switching between the two drugs; most of what's known comes from prescriber experience and general pharmacokinetic reasoning rather than a dedicated randomized trial. If you're considering a switch, that's a conversation for whoever is managing your prescription, not a decision to make from a forum post or a dosing calculator alone.

Which one is FDA-approved for what?

This distinction gets blurred constantly in casual comparisons, so it's worth stating plainly. | Brand | Compound | FDA-approved for |

So which should you actually choose?

If pure average weight loss is the deciding factor and cost isn't a barrier, the trial evidence favors tirzepatide. SURMOUNT-5's head-to-head result (20.2% vs. 13.7% average weight loss) is about as clean a comparison as this category has produced ^[4], and it's echoed by the separate SURPASS-2 diabetes trial showing tirzepatide outperforming semaglutide on both HbA1c and weight ^[7]. That said, "better on average" doesn't mean better for every individual. Some patients tolerate semaglutide's single-receptor mechanism with less nausea; some have insurance that only covers one drug or the other; some have a personal history (thyroid, pancreatitis, gallbladder) that changes the risk-benefit math regardless of which drug performs better in a trial population. Cost is also a real constraint: neither drug is cheap at list price, and coverage rules for weight-management indications specifically are inconsistent across insurers. What I'd actually tell someone: don't pick a drug because of a headline percentage. Get evaluated by a prescriber who reviews your full history, including thyroid and pancreatic risk factors, and let the choice come out of that conversation, not out of a marketing comparison chart. If you go the tirzepatide route through a provider-reviewed access model like Tirz Rx, confirm the fulfilling pharmacy is licensed and that dosing and reconstitution guidance (see how to reconstitute Tirz Rx) comes from that pharmacy or your prescriber, not from a generic internet chart.

Frequently asked questions

Is tirzepatide the same as Ozempic?

No. Ozempic is brand-name semaglutide, a single-receptor GLP-1 drug from Novo Nordisk. Tirzepatide is a different molecule, a dual GLP-1/GIP receptor agonist from Eli Lilly, sold as Mounjaro (diabetes) or Zepbound (weight loss). They're both injectable weekly incretin drugs but are chemically distinct compounds with different FDA approvals and different trial results.

Which causes more weight loss, tirzepatide or Ozempic?

Tirzepatide, based on direct trial comparison. SURMOUNT-5 found tirzepatide produced 20.2% average body weight loss versus 13.7% for semaglutide 2.4 mg over 72 weeks in a head-to-head randomized trial (NCT05822830). Note Ozempic itself isn't FDA-approved for weight loss; the comparable semaglutide product for weight is Wegovy.

Is Zepbound the same drug as Mounjaro?

Yes, both contain tirzepatide made by Eli Lilly. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and, separately, for moderate-to-severe obstructive sleep apnea in adults with obesity. They're the same active compound with different approved indications and sometimes different dose packaging.

Does tirzepatide have worse side effects than Ozempic?

Not clearly worse. Both drugs cause similar gastrointestinal side effects (nausea, diarrhea, vomiting, constipation), and SURPASS-2 found comparable overall adverse event rates between tirzepatide and semaglutide. Both carry the same boxed warning for thyroid C-cell tumor risk and are contraindicated in people with a history of medullary thyroid carcinoma or MEN 2.

Can I switch from Ozempic to tirzepatide?

People do this under medical supervision, but there's no direct mg-to-mg conversion between the two drugs since they use completely different dosing scales. A prescriber typically restarts titration at a low tirzepatide dose rather than matching your prior semaglutide dose. This isn't something to manage yourself without a prescriber involved.

Is compounded tirzepatide legal?

It can be, under specific conditions. FDA-registered compounding pharmacies (503A or 503B) may legally prepare tirzepatide when it meets criteria like clinical need for a customized formulation, but the FDA states compounded drugs "are not FDA-approved" and aren't reviewed by FDA for safety or effectiveness before marketing. Legality depends heavily on the specific pharmacy and formulation.

How much cheaper is compounded tirzepatide than Zepbound or Ozempic?

Compounded tirzepatide has generally cost less per month than Zepbound's roughly $1,000+ list price or Ozempic's roughly $997+ list price, though exact pricing varies by pharmacy and dose. Since FDA and Lilly confirmed tirzepatide was no longer in shortage in late 2024, the legal basis for shortage-based compounding narrowed, which has changed availability.

Which drug is FDA-approved for sleep apnea?

Zepbound (tirzepatide) is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, in addition to weight management. Neither Ozempic nor Wegovy (semaglutide) carries a sleep apnea indication as of current FDA labeling.

Does Ozempic or tirzepatide work better for type 2 diabetes?

Trial data favors tirzepatide for glycemic control. SURPASS-2 (NCT03987919) found tirzepatide superior to semaglutide 1 mg for HbA1c reduction and weight loss across all three tested doses in adults with type 2 diabetes, with the NEJM report describing tirzepatide as noninferior and superior to semaglutide on the primary endpoint.

What's the starting dose for each drug?

Tirzepatide (Zepbound/Mounjaro) starts at 2.5 mg once weekly, titrating up to a max of 15 mg. Semaglutide (Ozempic) starts at 0.25 mg weekly (a non-therapeutic starter dose), titrating toward a maintenance dose; Wegovy's max approved dose is 2.4 mg weekly. Titration for both typically proceeds in four-week steps.

Are tirzepatide and Ozempic safe for people with thyroid problems?

Neither is safe for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); both carry an FDA boxed warning for thyroid C-cell tumor risk based on rodent studies. This is a class-wide warning for GLP-1 and GIP/GLP-1 agonists, not specific to one brand.

Why does everyone call all these drugs 'Ozempic' even when they mean tirzepatide?

Ozempic was one of the first GLP-1 drugs to get wide media attention for off-label weight loss use, so the name became a generic stand-in for the whole drug category in casual speech, similar to how "Kleenex" gets used for tissues generally. It's imprecise: Ozempic, Wegovy, Mounjaro, and Zepbound are different products with different approvals.

Is tirzepatide stronger than semaglutide milligram for milligram?

The two drugs use entirely different dosing scales, so milligram amounts aren't directly comparable (tirzepatide tops out at 15 mg; semaglutide's Wegovy max is 2.4 mg). What's comparable is clinical effect at each drug's respective approved maximum dose, and by that measure tirzepatide has shown greater average weight loss and glycemic improvement in head-to-head trial data.

Sources

1. FDA, Mounjaro (tirzepatide) label: Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes
2. FDA, Zepbound (tirzepatide) prescribing information: Zepbound dosing schedule, boxed warning, contraindications, and adverse effect profile
3. Eli Lilly / SURMOUNT-5 trial listing, ClinicalTrials.gov: SURMOUNT-5 head-to-head trial of tirzepatide vs semaglutide 2.4mg for weight loss
4. ClinicalTrials.gov, SURMOUNT-1 trial record: SURMOUNT-1 trial design and tirzepatide weight loss results at 72 weeks
5. ClinicalTrials.gov, STEP 1 trial record: STEP 1 trial of semaglutide 2.4mg for weight management, average weight loss result
6. ClinicalTrials.gov, SURPASS-2 trial record: SURPASS-2 head-to-head trial of tirzepatide vs semaglutide 1mg in type 2 diabetes
7. FDA, Wegovy (semaglutide) prescribing information: Wegovy dosing schedule, boxed warning, and adverse effect profile
8. FDA, Compounding and the FDA: Questions and Answers: Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing
9. FDA, Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss: FDA warnings about compounded semaglutide/tirzepatide salt forms and counterfeit products
10. Eli Lilly, Zepbound pricing and LillyDirect information: Zepbound list price and lower-cost cash-pay vial options through LillyDirect